Education
About Us
Working with TipRanks
Follow Us
BiomX (PHGE)
:PHGE
PHGE Stock Chart & Stats
$4.47
-$0.09(-11.33%)
At close: 4:00 PM EST
$4.47
-$0.09(-11.33%)
Day’s Range― - ―
52-Week Range$1.50 - $14.71
Previous CloseN/A
Volume30.96K
Average Volume (3M)1.32M
Market Cap
$6.81M
Enterprise Value$3.29M
Total Cash (Recent Filing)$4.96M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta0.51
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,593,703
10 Day Avg. Volume1,108,900
30 Day Avg. Volume1,322,820
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-100.26
Price to Sales (P/S)0.00
P/FCF Ratio-4.95
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.22
Enterprise Value/Ebitda-0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Enrollment Progress In EuropeEnrollment in European sites continues ahead of plan, supporting patient recruitment momentum while the U.S. study is on hold.
Regulatory Support And Commercial Opportunity For BX011Positive FDA feedback and guidance support advancing BX011 into a Phase 2a study for diabetic foot infections, offering access to a larger patient population and greater commercial potential.
Trial Continuity And Safety OversightIndependent data monitoring committee recommended continuation of the BX004 cystic fibrosis study with protocol amendments, indicating oversight confidence in managing observed adverse events.
Bears Say
Delayed Top-line Data Increasing Financing RiskPostponement of expected cystic fibrosis topline data pushes results later and amplifies the company's financing risk.
Financing And Liquidity RiskSecuring additional financing is a stated priority, reflecting potential liquidity constraints that could affect program advancement.
Regulatory Hold Due To Device ScrutinyFDA inquiries about a third-party nebulizer have placed the U.S. cystic fibrosis study on hold, creating regulatory uncertainty about trial continuation.
BiomX News
PHGE FAQ
What was BiomX’s price range in the past 12 months?
BiomX lowest stock price was $1.50 and its highest was $14.71 in the past 12 months.
What is BiomX’s market cap?
BiomX’s market cap is $6.81M.
When is BiomX’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BiomX’s earnings last quarter?
Currently, no data Available
Is BiomX overvalued?
According to Wall Street analysts BiomX’s price is currently Overvalued.
Does BiomX pay dividends?
BiomX does not currently pay dividends.
What is BiomX’s EPS estimate?
BiomX’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BiomX have?
BiomX has 1,593,703 shares outstanding.
What happened to BiomX’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BiomX?
Currently, no hedge funds are holding shares in PHGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BiomX
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
PHGE Earnings Call
Q3 2025
0:00 / 0:00